Recent Updates
Recently added Catalysts
SGHT Positive Sentiment Score: 65/100

Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

Key Takeaway: Sight Sciences, Inc. announced that it will report its financial results for the fourth quarter and full year of 2022 on March 13, 2023, after the market closes. The management team will hold a conference call to discuss these results at 1:30 p.m. PT. The company focuses on developing innovative eyecare solutions, including minimally invasive surgical devices targeting prevalent eye diseases. Investors can access the conference call live and it will be archived for later listening.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sight Sciences is set to report its financial results, indicating ongoing business operations.
  • The company is focused on innovative eyecare solutions that improve patient lives.
  • Management will discuss financial outcomes in a forthcoming conference call, encouraging investor engagement.

Full Press Release Details

MENLO PARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2022, after the market close on Monday, March 13, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.

Frequently Asked Questions

When will Sight Sciences report its financial results?

Sight Sciences will report its fourth quarter and full year results on March 13, 2023.

How can I access the conference call for financial results?

The conference call can be accessed via a live and archived webcast on the Sight Sciences website.

What is the OMNI® Surgical System used for?

The OMNI® Surgical System is a device for minimally invasive glaucoma surgery to reduce eye pressure.

What condition does the TearCare® System treat?

The TearCare® System treats evaporative dry eye disease caused by meibomian gland dysfunction.

Last updated: Feb 23, 2023